Identification of potential drug-like molecules for inhibition of the inflammatory activity of cyclooxygenase-2

References

• Amadei, A., Linssen, A. B. M., & Berendsen, H. J. C. (1993). Essential dynamics of proteins. Proteins: Structure, Function, and Genetics, 17(4), 412–425. doi:10.1002/prot.340170408
   PubMed Web of Science ®Google Scholar
• Andricioaei, I., & Karplus, M. (2001). On the calculation of entropy from covariance matrices of the atomic fluctuations. The Journal of Chemical Physics, 115(14), 6289–6292. doi:10.1063/1.1401821
   Web of Science ®Google Scholar
• Baker, C. S. R., Hall, R. J. C., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., … Polak, J. M. (1999). Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(3), 646–655. doi:10.1161/01.ATV.19.3.646
   PubMed Web of Science ®Google Scholar
• Bowie, J. U., Luthy, R., & Eisenberg, D. (1991). A method to identify protein sequences that fold into a known three-dimensional structure. Science, 253(5016), 164–170. doi:10.1126/science.1853201
   PubMed Web of Science ®Google Scholar
• Burleigh, M., Babaev, V., Yancey, P., Major, A., Mccaleb, J., Oates, J., … Linton, M. (2005). Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. Journal of Molecular and Cellular Cardiology, 39(3), 443–452. doi:10.1016/j.yjmcc.2005.06.011
   PubMed Web of Science ®Google Scholar
• Cipollone, F., & Fazia, M. L. (2006). Cyclooxygenase-2 inhibition: Vascular inflammation and cardiovascular risk. Current Atherosclerosis Reports, 8(3), 245–251. doi:10.1007/s11883-006-0080-2
   PubMedGoogle Scholar
• Crofford, L. J. (1997). COX-1 and COX-2 tissue expression: Implications and predictions. The Journal of Rheumatology, 49, 15–19.
   Google Scholar
• Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., A., Van De Putte, L. B., & Lipsky, P. E. (1998). Cyclooxygenase in biology and disease. FASEB Journal, 12(12), 1063–1073.
   PubMed Web of Science ®Google Scholar
• Fava, C., & Montagnana, M. (2018). Atherosclerosis is an inflammatory disease which lacks a common anti-inflammatory therapy: How human genetics can help to this issue. A narrative review. Frontiers in Pharmacology, 9, 55. doi:10.3389/fphar.2018.00055
   PubMed Web of Science ®Google Scholar
• Grosser, T., Fries, S., & FitzGerald, G. A. (2005). Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. Journal of Clinical Investigation, 116(1), 4–15. doi:10.1172/JCI27291
   Web of Science ®Google Scholar
• Guex, N., & Peitsch, M. C. (1997). SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis, 18(15), 2714–2723. doi:10.1002/elps.1150181505
   PubMed Web of Science ®Google Scholar
• Gurung, A. B., & Bhattacharjee, A. (2017). Structure based virtual screening identifies Pranlukast as a potential inhibitor against Plasmodium falciparum adenosine deaminase enzyme. Gene Reports, 6, 54–66. doi:10.1016/j.genrep.2016.12.003
   Web of Science ®Google Scholar
• Gurung, A. B., Bhattacharjee, A., & Ali, M. A. (2016). Exploring the physicochemical profile and the binding patterns of selected novel anticancer Himalayan plant derived active compounds with macromolecular targets. Informatics in Medicine Unlocked, 5, 1–14. doi:10.1016/j.imu.2016.09.004
   Google Scholar
• Gurung, A. B., Mayengbam, B., & Bhattacharjee, A. (2018). Discovery of novel drug candidates for inhibition of soluble epoxide hydrolase of arachidonic acid cascade pathway implicated in atherosclerosis. Computational Biology and Chemistry, 74, 1–11. doi:10.1016/j.compbiolchem.2018.02.019
   PubMed Web of Science ®Google Scholar
• Hess, B., Kutzner, C., Van Der Spoel, D., & Lindahl, E. (2008). GRGMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. Journal of Chemical Theory and Computation, 4(3), 435–447. doi:10.1021/ct700301q
   PubMed Web of Science ®Google Scholar
• Homeyer, N., & Gohlke, H. (2012). Free energy calculations by the molecular mechanics Poisson-Boltzmann surface area method. Molecular Informatics, 31(2), 114–122. doi:10.1002/minf.201100135
   PubMed Web of Science ®Google Scholar
• Jones, G., Willett, P., Glen, R. C., Leach, A. R., & Taylor, R. (1997). Development and validation of a genetic algorithm for flexible docking. Journal of Molecular Biology, 267(3), 727–748. doi:10.1006/jmbi.1996.0897
   PubMed Web of Science ®Google Scholar
• Kumari, R., Kumar, R., & Lynn, A. (2014). g_mmpbsa–a GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. doi:10.1021/ci500020m
   PubMed Web of Science ®Google Scholar
• Lane, N. E. (1997). Pain management in osteoarthritis: The role of COX-2 inhibitors. Journal of Rheumatology, 49, 20–24.
   Google Scholar
• Laskowski, R. A., & Swindells, M. B. (2011). LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling, 51(10), 2778–2786. doi:10.1021/ci200227u
   PubMed Web of Science ®Google Scholar
• Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868–874. doi:10.1038/nature01323
   PubMed Web of Science ®Google Scholar
• Lipinski, C. A. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today: Technologies, 1(4), 337–341. doi:10.1016/j.ddtec.2004.11.007
   PubMedGoogle Scholar
• Llorca, O., Betti, M., Gonzalez, J. M., Valencia, A., Marquez, A. J., & Valpuesta, J. M. (2006). The three-dimensional structure of an eukaryotic glutamine synthetase: Functional implications of its oligomeric structure. Journal of Structural Biology, 156(3), 469–479. doi:10.1016/j.jsb.2006.06.003
   PubMed Web of Science ®Google Scholar
• Luthy, R., Bowie, J. U., & Eisenberg, D. (1992). Assessment of protein models with three-dimensional profiles. Nature, 356(6364), 83–85. doi:10.1038/356083a0
   PubMed Web of Science ®Google Scholar
• Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry, 30(16), 2785–2791. doi:10.1002/jcc.21256
   PubMed Web of Science ®Google Scholar
• Murray, C. J. L., & Lopez, A. D. (1997). Global mortality, disability, and the contribution of risk factors: Global burden of disease study. The Lancet, 349(9063), 1436–1442. doi:10.1016/S0140-6736(96)07495-8
   PubMed Web of Science ®Google Scholar
• Olesen, M., Kwong, E., Meztli, A., Kontny, F., Seljeflot, I., Arnesen, H., … Falk, E. (2002). No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scandinavian Cardiovascular Journal, 36(6), 362–367. doi:10.1080/140174302762659094
   PubMed Web of Science ®Google Scholar
• Praticò, D., Tillmann, C., Zhang, Z.-B., Li, H., & FitzGerald, G. A. (2001). Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proceedings of the National Academy of Sciences, 98(6), 3358–3363. doi:10.1073/pnas.061607398
   PubMed Web of Science ®Google Scholar
• Sander, T., Freyss, J., von Korff, M., & Rufener, C. (2015). DataWarrior: An open-source program for chemistry aware data visualization and analysis. Journal of Chemical Information and Modeling, 55(2), 460–473. doi:10.1021/ci500588j
   PubMed Web of Science ®Google Scholar
• Schönbeck, U., Sukhova, G. K., Graber, P., Coulter, S., & Libby, P. (1999). Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. The American Journal of Pathology, 155(4), 1281–1291. doi:10.1016/S0002-9440(10)65230-3
   PubMed Web of Science ®Google Scholar
• SchuÈttelkopf, A. W., & Van Aalten, D. M. F. (2004). PRODRG: A tool for high-throughput crystallography of protein–ligand complexes. Acta Crystallographica Section D Biological Crystallography, 60(8), 1355–1363. doi:10.1107/S0907444904011679
   PubMedGoogle Scholar
• Schwede, T., Kopp, J., Guex, N., & Peitsch, M. C. (2003). SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Research, 31(13), 3381–3385. doi:10.1093/nar/gkg520
   PubMed Web of Science ®Google Scholar
• Sippl, M. J. (1993). Recognition of errors in three-dimensional structures of proteins. Proteins: Structure, Function, and Genetics, 17(4), 355–362. doi:10.1002/prot.340170404
   PubMed Web of Science ®Google Scholar
• Taleb, S. (2016). Inflammation in atherosclerosis. Archives of Cardiovascular Diseases, 109(12), 708–715. doi:10.1016/j.acvd.2016.04.002
   PubMed Web of Science ®Google Scholar
• Tedgui, A., & Mallat, Z. (2006). Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiological Reviews, 86(2), 515–581. doi:10.1152/physrev.00024.2005
   PubMed Web of Science ®Google Scholar
• Verdonk, M. L., Cole, J. C., Hartshorn, M. J., Murray, C. W., & Taylor, R. D. (2003). Improved protein–ligand docking using GOLD. Proteins: Structure, Function, and Bioinformatics, 52(4), 609–623. doi:10.1002/prot.10465
   PubMed Web of Science ®Google Scholar
• Weber, C., Zernecke, A., & Libby, P. (2008). The multifaceted contributions of leukocyte subsets to atherosclerosis: Lessons from mouse models. Nature Reviews Immunology, 8(10), 802. doi:10.1038/nri2415
   PubMed Web of Science ®Google Scholar
• Wiederstein, M., & Sippl, M. J. (2007). ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Research, 35(Web Server), W407–W410. doi:10.1093/nar/gkm290
   PubMed Web of Science ®Google Scholar
• Zarghi, A., & Arfaei, S. (2011). Selective COX-2 inhibitors: A review of their structure-activity relationships. Iranian Journal of Pharmaceutical Research, 10(4), 655.
   PubMed Web of Science ®Google Scholar